Dulanermin

Summary

Dulanermin is a recombinant, soluble form of the human tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL). It is an investigational biologic being evaluated primarily in combination with standard chemotherapy for advanced solid tumours such as non‑small‑cell lung cancer (NSCLC) and metastatic colorectal cancer. The drug is administered intravenously and is intended to trigger tumour‑cell specific apoptosis through death‑receptor activation.

Mechanism of Action

Dulanermin mimics endogenous TRAIL and binds to the death receptors DR4 (TRAIL‑R1) and DR5 (TRAIL‑R2) on the surface of cells. Receptor engagement leads to formation of the death‑inducing signalling complex, activation of initiator caspases (caspase‑8/10), and downstream executioner caspases (caspase‑3/7), resulting in programmed cell death. Normal cells express decoy receptors or anti‑apoptotic proteins, which limits toxicity and gives TRAIL‑based agents a tumour‑selective profile.

What the Research Shows

A phase III trial in 452 untreated advanced NSCLC patients added dulanermin (75 µg/kg days 1–14) to vinorelbine‑cisplatin and showed a statistically significant extension of median progression‑free survival (6.4 vs 3.5 months) and higher objective response rate (46.8% vs 30%), but no overall‑survival benefit. Earlier phase II and phase 1b NSCLC studies combining dulanermin with paclitaxel, carboplatin, bevacizumab, or NP chemotherapy reported response rates up to 58% and median PFS around 7 months, with a tolerable safety profile. A phase 1b trial in metastatic colorectal cancer combined dulanermin with FOLFOX6 and bevacizumab, achieving a 57% partial‑response rate and median PFS of 9.9 months. Early‑phase pharmacodynamic work demonstrated transient serum increases in caspase‑3/7 and cytokeratin‑18 after dosing, supporting target engagement, though clinical responses were modest. Overall, the data indicate activity in selected settings but inconsistent efficacy across tumour types and patient populations.

Reported Benefits

Clinical data suggest that dulanermin can improve progression‑free survival and tumour response when added to certain chemotherapy backbones, as seen in a large NSCLC phase III study. Early‑phase trials have reported objective response rates ranging from 40% to 58% in NSCLC and colorectal cancer, indicating potential antitumour activity. The agent has generally been well tolerated, with most adverse events attributable to the accompanying chemotherapy rather than dulanermin itself.

Limitations of the Evidence

The survival advantage of dulanermin remains unproven; the phase III NSCLC trial did not improve overall survival. Phase II NSCLC data showed no benefit in unselected patients, highlighting the need for predictive biomarkers. Many studies are early‑phase, single‑arm, or involve small cohorts, limiting the strength of efficacy conclusions. Responses appear heterogeneous across tumour types, and no randomized data exist for colorectal cancer. Further large, controlled trials are required to define its therapeutic role.

Safety Considerations

Across trials, the most frequent grade ≥ 3 toxicities were cytopenias (neutropenia, leukopenia, anemia) and chemotherapy‑related events such as hypertension, peripheral neuropathy, hand‑foot syndrome, and pulmonary embolism. Dulanermin‑related adverse events were generally mild (grade 1‑2) and no dose‑limiting toxicities were identified in phase 1b studies. Overall incidence of serious adverse events was comparable to chemotherapy alone, but clinicians should monitor blood counts and manage standard chemotherapy toxicities when using dulanermin.

How It Is Administered

Dulanermin is administered intravenously, typically as a short infusion on consecutive days (e.g., five daily doses or two consecutive doses) repeated every three weeks. It is given in combination with standard chemotherapy regimens such as vinorelbine‑cisplatin, paclitaxel‑carboplatin‑bevacizumab, or FOLFOX6‑bevacizumab. Formulations used in trials are recombinant human protein solutions prepared for IV infusion.

Routes of Administration

Goals & Uses

• Colorectal cancer treatmentOncologyModerate
• Non-small cell lung cancer treatmentOncologyModerate
• Synergistic combination with chemotherapyOncologyModerate
• Apoptosis induction in tumor cellsAnticancerModerate
• Combination therapy with chemotherapyOncologyModerate
• Selective cancer cell killingTargeted TherapyModerate
• Solid tumor cytoreductionOncologyModerate

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Active severe infectionInfectiousModerate
• Hepatic impairmentOrgan DysfunctionHigh
• Severe uncontrolled infectionInfectionModerate

Adverse Effects

• Hepatotoxicity / elevated liver enzymesHepaticUncommon
• ThrombocytopeniaHematologicUncommonLow platelet count
• Infusion‑related reactions (fever, chills, hypotension)GeneralCommon
• Elevated liver enzymes (ALT/AST)HepaticUncommon
• Nausea and vomitingGastrointestinalCommon
• FatigueGeneralCommonLow energy or tiredness
• Cytopenias (neutropenia, thrombocytopenia)HematologicRare
• Infusion-related reactionsHypersensitivityUncommon

Drug Interactions

• BevacizumabLow
• Chemotherapeutic agents (e.g., gemcitabine, 5‑FU)Moderate
• FOLFOXLow
• Carboplatin/PaclitaxelLow
• CorticosteroidsLow

Population Constraints

• Pediatric patientsAgeRelative
• Patients with pre-existing hepatic diseaseOrgan DysfunctionRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Elderly (>75 years)GeriatricRelative

Regulatory Status

• European UnionInvestigationalClinical trial authorization only.
• United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
• United KingdomInvestigationalNot licensed; used under Clinical Trial Authorisation.

Never received marketing approval; evaluated in Phase I–III trials for solid tumours and hematologic malignancies.

Evidence & Sources

• Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
  Journal ArticleModerateOuyang X, et al.2018-01-01T00:00:00.000000Z
• Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
  Journal ArticleModerateSoria JC, et al.2011-01-01T00:00:00.000000Z
• Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer
  Journal ArticleModerateSoria JC, et al.2010-01-01T00:00:00.000000Z
• Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
  Journal ArticleModerateHolland PM2013-01-01T00:00:00.000000Z
• A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
  Journal ArticleModerateWainberg ZA, et al.2013-01-01T00:00:00.000000Z
• Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
  Journal ArticleModeratePan Y, et al.2011-01-01T00:00:00.000000Z

Frequently Asked Questions